Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
MWN-AI** Summary
Coya Therapeutics, Inc. has announced a significant publication highlighting the role of regulatory T-cell (Treg) dysfunction and systemic inflammation in frontotemporal dementia (FTD). The research, led by Dr. Alireza Faridar and Dr. Stanley Appel from the Houston Methodist Neurological Institute, analyzes blood samples from 27 FTD patients compared to 25 age-matched healthy individuals and reveals marked reductions in Treg function and increases in pro-inflammatory cytokines and chemokines in FTD patients. The study's findings suggest a crucial involvement of the peripheral immune system in the neuroinflammatory profile of FTD, supporting the mechanistic rationale for the company's investigational immunotherapy, COYA 302.
Dr. Fred Grossman, Coya's Chief Medical Officer, expressed optimism that these biomarker findings, combined with positive clinical outcomes from a prior study involving low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, underpin the need for therapies that enhance Treg function and address inflammation in neurodegenerative conditions. The published research aligns with results from an investigator-initiated trial, which showed that LD IL-2 and CTLA-4 Ig could restore Treg activity and reduce inflammatory markers in treated FTD patients. Furthermore, treatment with this biologic combination showed promise by preventing cognitive decline over a 22-week period, with minimal side effects reported.
Coya Therapeutics, headquartered in Houston, prioritizes the development of therapies to restore Treg functions in various diseases characterized by inflammation, including FTD and ALS. Their investigational product COYA 302 is at the forefront of clinical trials aimed at mitigating disease progression through innovative therapeutic modalities targeting systemic inflammation.
MWN-AI** Analysis
Coya Therapeutics (NASDAQ: COYA) released promising study findings indicating significant dysregulation of regulatory T-cell (Treg) function and systemic inflammation in patients with frontotemporal dementia (FTD). These results support the clinical rationale for their investigational therapy, COYA 302, a biologic designed to restore Treg functions while targeting neuroinflammation, a central mechanism in various neurodegenerative diseases, including FTD and ALS.
The study, conducted at the Houston Methodist Neurological Institute, highlights critical biomarkers showing a marked reduction in Treg function and an increase in pro-inflammatory cytokines in FTD patients. This creates a compelling narrative around the necessity of therapies that can modulate the immune response effectively. Given the aging population and the rising prevalence of neurodegenerative diseases, Coya is positioned in a potentially lucrative market with a high unmet medical need.
Investors should consider several factors when evaluating Coya's prospects. The promising results of their biomarker study provide validation for COYA 302. Additionally, the ongoing ALSTARS trial, aimed at assessing COYA 302's efficacy in ALS, reinforces confidence in the company's direction. While the absence of approved therapies for FTD enhances Coya's position, investors should remain cautious about the risks associated with clinical-stage biotech investments, including regulatory hurdles and the inherent uncertainty of clinical trial outcomes.
Coya's innovative approach to leveraging Treg biology could transform how neurodegenerative conditions are treated, driving long-term value for the company. For risk-averse investors, monitoring trial progress and upcoming data releases will be crucial. Overall, Coya Therapeutics represents a speculative yet optimistic investment opportunity in the biotech landscape focused on neuroinflammatory diseases.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD
Low-dose IL-2 plus CTLA-4 Ig has previously demonstrated restoration of regulatory T-cell function together with reduction of inflammatory cytokines and monocyte activation in treated patients
Findings of this biomarker study are consistent with previously reported results of an Investigator-Initiated-Trial of LD IL-2 and CTLA-4 Ig in patients with FTD
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia (FTD). The study has been published in the peer-reviewed journal Brain Communications and can be accessed here .
Dr. Fred Grossman, Chief Medical Officer at Coya said, “We believe these biomarker data coupled with the clinical and lab results of the clinical study in FTD provide additional evidence supporting the development of biologic combination therapies that enhance the function of regulatory T cells and target inflammation in FTD, ALS and other neurodegenerative diseases of high unmet need.”
Summary of Study Results
Blood samples were obtained from 27 patients clinically diagnosed with FTD and 25 age-matched healthy individuals as a control group.
Comprehensive analyses revealed significantly lower regulatory T cell (Treg) immunomodulatory suppressive function in FTD patients compared to healthy controls (p<0.05). Transcriptomic profiling of monocytes showed different degrees of dysregulation of immune-related genes in samples from FTD patients. Consistent with the reduced anti-inflammatory function observed in Tregs, proteomic analysis of plasma inflammatory mediators showed a significant increase in the pro-inflammatory cytokine TNF? (tumor necrosis factor-alpha) (p<0.05) and the chemokines CXCL10 (C-X-C motif chemokine ligand 10), CCL3 (C-C motif chemokine ligand 3), CCL19 (C-C motif chemokine ligand 19), CSF1 (macrophage colony-stimulating factor) (p<0.05) and CXCL12 (C-X-C motif chemokine ligand 12) (p<0.01) in FTD patients compared to healthy controls.
The Company believes the results of this study demonstrate that there is a dysregulation of inflammation-related gene expression in peripheral monocytes and an increase of plasma inflammatory chemokines and cytokines in FTD. In addition, the data provide evidence of compromised immunomodulatory function of Tregs.
The Company believes that biomarker data from this research study further support the previously reported findings of an academic clinical study of low-dose interleukin 2 (LD IL-2) and CTLA-4 Ig in patients with FTD. The subcutaneous administration of LD IL-2 and CTLA-4 Ig significantly increased the number and function of Tregs as early as 2 weeks after initiation of treatment and remained elevated throughout the study. Consistent with the improvement of Treg immunomodulatory function, study patients did not show clinical cognitive decline as measured by the validated tools MoCA (Montreal Cognitive Assessment) and CDR-FTLD (Clinical Dementia Rating-Frontotemporal Lobar Degeneration module) over the 22-week treatment period. Overall, treatment with LD IL-2 and CTLA-4 Ig was well tolerated. The most frequent adverse events were mild injection-site erythema.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.
Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
For more information about Coya, please visit www.coyatherapeutics.com
About Frontotemporal Dementia
Frontotemporal dementia (FTD) also referred as frontotemporal lobar degeneration (FTLD), is a progressive neurodegenerative orphan disease affecting the frontal and temporal lobes, causing changes in behavior, language, and personality rather than initial memory loss. It is the most common dementia for people under 60, typically surfacing between ages 45-65, with symptoms worsening over time. There is no currently approved treatment to modify the progression of FTD. 1
1. National Institute of Neurological Disorders and Stroke, National Institutes of Health (2026) |
About COYA 302
COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS and other neurodegenerative diseases. These mechanisms may have additive or synergistic effects.
Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS ( ClinicalTrials.gov Identifier: NCT 07161999).
COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260318067300/en/
Investor Contact
David Snyder, CFO
david@coyatherapeutics.com
Media Contacts
Russo Partners
David Schull
David.Schull@russopartnersllc.com
858-717-2310
Rachelle Babb
rachelle.babb@russopartnersllc.com
929-325-7559
FAQ**
How does Coya Therapeutics Inc. COYA plan to address the dysregulation of inflammation-related gene expression observed in patients with FTD through its investigational therapies?
2. What impact do the findings from the recent study have on Coya Therapeutics Inc. COYA's strategy for developing treatments for neurodegenerative diseases like ALS and FTD?
3. Can Coya Therapeutics Inc. COYA provide insights on the safety profile of COYA 302 based on the adverse events reported during the clinical studies?
4. What are the next steps for Coya Therapeutics Inc. COYA following the promising results from the ALSTARS Trial in terms of advancing COYA 302 towards regulatory approval?
**MWN-AI FAQ is based on asking OpenAI questions about Coya Therapeutics Inc. (NASDAQ: COYA).
NASDAQ: COYA
COYA Trading
-4.31% G/L:
$4.66 Last:
120,659 Volume:
$5.06 Open:
